

Special Issue

Therapeutic Agents for Neurodegenerative Disorders

Message from the Guest Editors

This Special Issue of *Molecules* provides a forum for the dissemination of the most recent findings on therapeutic agents for neurodegenerative diseases. Neurodegenerative diseases such as Alzheimer's, Parkinson's, and Huntington's diseases as well as amyotrophic lateral sclerosis pose extraordinary challenges for drug development. There is a great need for therapies to prevent and/or slow the progression of these disorders. A number of these therapeutic targets also serve multiple roles as biomarkers and as theranostics. Drug designs have also shifted from treating neurodegenerative diseases at later stages of disease progression to focusing on preventive strategies at early stages of disease development. We welcome the submission of research and review articles on the advances in every aspect of drug discovery in the field of neurodegenerative diseases.

Guest Editors

Dr. Andrea Kwakowsky

Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand

Dr. Margaret Ryan

Brain Health Research Centre, University of Otago, PO Box 56, Dunedin, New Zealand

Deadline for manuscript submissions

closed (30 November 2023)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/101018

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).